Jia Jie Biomedical Co Ltd (4109) — Capital Reinvestment Ratio
Jia Jie Biomedical Co Ltd (4109) has a Capital Reinvestment Ratio of 2.51x as of December 2025, meaning it reinvests 3% of its operating cash flow (NT$11.32 Million) in capital expenditures (NT$28.47 Million). See 4109 net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Jia Jie Biomedical Co Ltd Capital Reinvestment Ratio (2015–2025)
This chart tracks Jia Jie Biomedical Co Ltd's Capital Reinvestment Ratio across 6 annual periods. Check how aggressively does Jia Jie Biomedical Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Jia Jie Biomedical Co Ltd (2015–2025)
Year-by-year Capital Reinvestment Ratio for Jia Jie Biomedical Co Ltd from 2015 to 2025. For live market cap and broader valuation context, see 4109 market cap overview.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 4.01x | NT$21.34 Million | NT$85.50 Million | ▲ +805.1% |
| 2024 | 0.44x | NT$44.35 Million | NT$19.63 Million | ▲ +27.4% |
| 2021 | 0.35x | NT$4.37 Million | NT$1.52 Million | ▲ +476.4% |
| 2020 | 0.06x | NT$27.10 Million | NT$1.63 Million | ▼ -51.2% |
| 2019 | 0.12x | NT$24.71 Million | NT$3.05 Million | ▼ -96.3% |
| 2015 | 3.33x | NT$82.22 Million | NT$273.85 Million | — |